REFLEXION MEDICAL, INC.

HAYWARD, CA · CIK 0001604459 · Medtech · Private

Biology-guided radiotherapy system using real-time PET imaging for autonomous tumor tracking and dose delivery to multiple lesions

reflexion.com →
Grants
$2.6M
5 awards
Sector median: 1
Raised
$413M
6 Form D · Nov 2023
35 months since last filing
Contracts
—
No federal contracts on record
Patents
40
16 granted · 24 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$6,144,117
Federal grantDepartment of Health and Human Services · Phase II · Rotating PET and linear accelerator system for PET-guided radiation therapy$264,232
Private capital raisedForm D · SEC$23,000,000
Federal grantDepartment of Health and Human Services · Phase II · Rotating PET and linear accelerator system for PET-guided radiation therapy$66,210
Private capital raisedForm D · SEC$96,499,991
Federal grantDepartment of Health and Human Services · Phase II · Pre-clinical validation and verification of a biology-guided radiation therapy system$300,000
Federal grantDepartment of Health and Human Services · Phase II · Pre-clinical validation and verification of a biology-guided radiation therapy system$1,050,000
Federal grantDepartment of Health and Human Services · Phase II · Pre-clinical validation and verification of a biology-guided radiation therapy system$950,000
Private capital raisedForm D · SEC$99,999,987
Private capital raisedForm D · SEC$80,672,959
Private capital raisedForm D · SEC$106,712,002
Federal grant · SBIR/STTRForm D · SEC

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1937FLUIDISPEC LLC——
1938CREATIVE SCIENTIST, INC.——
1939Cutting Edge Spine, llc—$1.3M
1940REFLEXION MEDICAL, INC.—$413M
1941Conformal Medical, Inc.—$145M
1942Oncocyte Corp—$83M
1943MORPHIX TECHNOLOGIES, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 41 related persons
  • Rana Al-HallaqDirector
  • Philip Aulson IIExecutive Officer
  • Judy Bartlett-RobertoExecutive Officer
  • Bill BurkothDirector
  • William BurkothDirector
  • BILL BURKOTHDirector
  • Colin CahillDirector
  • Greg GarfieldDirector
  • GREG GARFIELDDirector
  • Art HeidrichDirector
  • Matthew HobartDirector
  • MATTHEW HOBARTDirector
  • Jeff HolifieldExecutive Officer
  • Jeffrey HolifieldExecutive Officer
  • Loic JuleDirector
  • Leena KadakiaExecutive Officer
  • Nael KassarDirector
  • Diana KingExecutive Officer
  • Gopinath KuduvalliExecutive Officer
  • David LarkinExecutive Officer
  • David LeungExecutive Officer
  • Leonard LyonsExecutive Officer
  • Samuel MazinDirector · Executive Officer
  • SAMUEL MAZINDirector · Executive Officer
  • Thorsten MelcherExecutive Officer
  • Fred MollDirector
  • FRED MOLLDirector
  • Akshay NanduriDirector · Executive Officer
  • Kathy O'ShaughnessyExecutive Officer
  • Antoine PapiernikDirector
  • ANTOINE PAPIERNIKDirector
  • Todd PowellDirector · Executive Officer
  • TODD POWELLDirector · Executive Officer
  • Kevin ReillyDirector
  • Renee RyanDirector
  • Alice SchroederDirector
  • Sean ShirvaniExecutive Officer
  • Cem UsakliDirector
  • Jay WatkinsDirector
  • JAY WATKINSDirector
  • Martyn WebsterExecutive Officer

Patents

USPTO · 16 granted of 40

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.